Investigating a drug's effect on eye damage from radiation therapy
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
This study is looking at how a drug called rusalatide acetate might help protect the eyes of people who have had radiation therapy for head and neck cancers, with the hope of reducing vision problems and discomfort caused by radiation damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Affirmed Pharma, LLC NIH-funded |
| Lab location | 1 site (Conroe, United States) |
| Project ID | NIH-10605739 on NIH RePORTER |
What this research studies
This research focuses on the impact of rusalatide acetate (TP508) in preventing or repairing damage to the cornea caused by radiation therapy, particularly in patients treated for head and neck cancers. The study uses a mouse model to explore how this drug can protect corneal epithelial cells, neurons, and lacrimal cells from radiation-induced harm. By understanding the mechanisms of radiation keratopathy, the research aims to improve the quality of life for affected patients by potentially mitigating vision loss and discomfort.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients receiving radiation therapy for head and neck malignancies who are at risk of developing radiation-induced keratopathy.
Not a fit: Patients who have not undergone radiation therapy or those with pre-existing severe corneal diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that reduce vision loss and enhance the quality of life for patients undergoing radiation therapy.
How similar studies have performed: Previous studies have shown promising results with similar approaches in mitigating radiation effects, indicating potential for success in this research.
Where this research is happening
Conroe, United States
- Affirmed Pharma, LLC — Conroe, United States (Active)
Researchers
- Principal investigator: Andley, Usha P — Affirmed Pharma, LLC
- Study coordinator: Andley, Usha P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.